Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation
- PMID: 17584768
- DOI: 10.1093/hmg/ddm151
Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation
Abstract
Pathogenic mutations in the leucine-rich repeat kinase-2 (LRRK2) gene cause autosomal-dominant and certain cases of sporadic Parkinson's disease (PD). The G2019S substitution in LRRK2 is the most common genetic determinant of PD identified so far, and maps to a specific region of the kinase domain called the activation segment. Here, we show that autophosphorylation of LRRK2 is an intermolecular reaction and targets two residues within the activation segment. The prominent pathogenic G2019S mutation in LRRK2 results in altered autophosphorylation, and increased autophosphorylation and substrate phosphorylation, through a process that seems to involve reorganization of the activation segment. Our results suggest a molecular mechanistic explanation for how the G2019S mutation enhances the catalytic activity of LRRK2, thereby leading to pathogenicity. These findings have important implications for therapeutic strategies in PD.
Similar articles
-
A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.Eur J Neurol. 2007 Apr;14(4):413-7. doi: 10.1111/j.1468-1331.2007.01685.x. Eur J Neurol. 2007. PMID: 17388990
-
MAPK-pathway activity, Lrrk2 G2019S, and Parkinson's disease.J Neurosci Res. 2007 May 1;85(6):1288-94. doi: 10.1002/jnr.21240. J Neurosci Res. 2007. PMID: 17385669
-
Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.Neurobiol Dis. 2015 May;77:49-61. doi: 10.1016/j.nbd.2015.02.019. Epub 2015 Feb 28. Neurobiol Dis. 2015. PMID: 25731749
-
LRRK2 in Parkinson's disease: genetic and clinical studies from patients.FEBS J. 2009 Nov;276(22):6455-63. doi: 10.1111/j.1742-4658.2009.07344.x. Epub 2009 Oct 5. FEBS J. 2009. PMID: 19804413 Review.
-
Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease.Biochem Soc Trans. 2012 Oct;40(5):1058-62. doi: 10.1042/BST20120054. Biochem Soc Trans. 2012. PMID: 22988865 Review.
Cited by
-
Parkinson's Disease Gene Screening in Familial Cases from Central and South America.Mov Disord. 2024 Oct;39(10):1843-1855. doi: 10.1002/mds.29931. Epub 2024 Jul 25. Mov Disord. 2024. PMID: 39051491
-
Defects in mRNA Translation in LRRK2-Mutant hiPSC-Derived Dopaminergic Neurons Lead to Dysregulated Calcium Homeostasis.Cell Stem Cell. 2020 Oct 1;27(4):633-645.e7. doi: 10.1016/j.stem.2020.08.002. Epub 2020 Aug 25. Cell Stem Cell. 2020. PMID: 32846140 Free PMC article.
-
Current understanding of LRRK2 in Parkinson's disease: biochemical and structural features and inhibitor design.Future Med Chem. 2012 Sep;4(13):1701-13. doi: 10.4155/fmc.12.110. Future Med Chem. 2012. PMID: 22924508 Free PMC article. Review.
-
The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation.J Biol Chem. 2008 Jun 13;283(24):16906-14. doi: 10.1074/jbc.M708718200. Epub 2008 Apr 8. J Biol Chem. 2008. PMID: 18397888 Free PMC article.
-
Mutant LRRK2 enhances glutamatergic synapse activity and evokes excitotoxic dendrite degeneration.Biochim Biophys Acta. 2014 Sep;1842(9):1596-603. doi: 10.1016/j.bbadis.2014.05.016. Epub 2014 May 27. Biochim Biophys Acta. 2014. PMID: 24874075 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical